<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40550724</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Efficacy of a single low dose of esketamine for patients with irritable bowel syndrome: study protocol for a randomised controlled trial.</ArticleTitle><Pagination><StartPage>e099793</StartPage><MedlinePgn>e099793</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e099793</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2025-099793</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">As a disorder of gut-brain interaction, irritable bowel syndrome (IBS) is a common reason for patient visits in primary and specialist care settings. IBS is associated with recurrent abdominal pain, altered bowel habit, resulting in alternating constipation and diarrhoea, bloating, without serious organic diseases. The bidirectional relationship between IBS and psychological factor is also complex. Studies have suggested that tricyclic antidepressants can effectively control the concomitant symptoms of IBS, especially some severe and refractory symptoms. At present, the conventional treatment of IBS remains somewhat unsatisfactory. Studies have shown that the antidepressant effects of esketamine are rapid and significant, whether a single low dose of esketamine is effective in IBS deserves further investigation. In this study, we hypothesise that a single low dose of esketamine will be effective for IBS.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">This is a single-centre, randomised, double-blind, placebo-controlled trial. Patients with IBS are divided into three levels according to the severity of IBS: mild, moderate and severe. 92 patients in the esketamine group and 92 patients in the control group who are scheduled for colonoscopy will be prospectively recruited in each level. The primary outcome is the IBS Severity Scoring System at baseline and at 3&#x2009;days, 1&#x2009;week, 3 weeks, 6 weeks after colonoscopy. The secondary outcome includes IBS-Quality of Life, Bristol Stool Form scale, Hospital Anxiety and Depression Scale, Patient Health Questionnaire-12 Somatic Symptom Score and adverse events. The allocation sequence is assigned by a random number table using a block randomisation method by SPSS (Version 26, IBM Inc., USA) Statistics software. All enrolled patients, anaesthesiologist B and researchers responsible for follow-up and data collection and analysis are therefore fully blinded. All data will be performed using SPSS Statistics software, and a p value &lt;0.05&#x2009;will be considered statistically significant.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">The protocol has been approved by the Medical Ethics Committee of Beijing Tiantan Hospital affiliated to Capital Medical University (KY2024-414-02). All participants will sign a written informed consent form. The results will be submitted for publication in peer-reviewed journals, presented at international conferences, and shared with participants via hospital newsletters.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">Efficacy of Esketamine for Patients With Irritable Bowel Syndrome (NCT06788444).</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Day Surgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Day Surgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Day Surgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Fang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8781-6576</Identifier><AffiliationInfo><Affiliation>Department of Pain Management, Beijing Tiantan Hospital, Beijing, China luofangwt@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06788444</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>50LFG02TXD</RegistryNumber><NameOfSubstance UI="C000629870">Esketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="Y">Ketamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Protocols</Keyword><Keyword MajorTopicYN="N">Irritable Bowel Syndrome</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trial</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>23</Day><Hour>21</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40550724</ArticleId><ArticleId IdType="pmc">PMC12186029</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2025-099793</ArticleId><ArticleId IdType="pii">bmjopen-2025-099793</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160:99&#x2013;114. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17:473&#x2013;86. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011:CD003460. doi: 10.1002/14651858.CD003460.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003460.pub3</ArticleId><ArticleId IdType="pmc">PMC8745618</ArticleId><ArticleId IdType="pubmed">21833945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17&#x2013;44. doi: 10.14309/ajg.0000000000001036.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome in 2021: a systematic review of prevalence and disease impact. Gut. 2022;71:1078&#x2013;89.</Citation></Reference><Reference><Citation>Fairbrass KM, Selinger CP, Gracie DJ, et al. Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2022;34:e14256. doi: 10.1111/nmo.14256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14256</ArticleId><ArticleId IdType="pubmed">34472157</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillil&#xe4; MT, Siivola MT, F&#xe4;rkkil&#xe4; MA. Comorbidity and use of health-care services among irritable bowel syndrome sufferers. Scand J Gastroenterol. 2007;42:799&#x2013;806. doi: 10.1080/00365520601113927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365520601113927</ArticleId><ArticleId IdType="pubmed">17558902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229&#x2013;39. doi: 10.1111/j.1572-0241.2007.01740.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01740.x</ArticleId><ArticleId IdType="pubmed">18371141</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome. Am J Gastroenterol. 2020;115:1246&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58:367&#x2013;78. doi: 10.1136/gut.2008.163162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2008.163162</ArticleId><ArticleId IdType="pubmed">19001059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Zhu H, Liu Y, et al. Ketamine restores gut-brain axis homeostasis in IBS patients with comorbid anxiety: a randomized controlled trial. Clin Gastroenterol Hepatol. 2023;21:e45&#x2013;58.</Citation></Reference><Reference><Citation>Mayer EA, Nance K, Chen S. The Gut-Brain Axis. Annu Rev Med. 2022;73:439&#x2013;53. doi: 10.1146/annurev-med-042320-014032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042320-014032</ArticleId><ArticleId IdType="pubmed">34669431</ArticleId></ArticleIdList></Reference><Reference><Citation>Houte K, Carbone F, T&#xf6;rnblom H, et al. Long-term outcomes of low FODMAP diet in IBS: high dropout rates limit sustained efficacy. Gut. 2025;74:112&#x2013;21.</Citation></Reference><Reference><Citation>Hinse M, Thronicke A, Bergh&#xf6;fer A. Multimodal anthroposophic therapy vs standard care in refractory IBS: a randomized trial. Gastroenterology. 2024;166:e789&#x2013;802.</Citation></Reference><Reference><Citation>Martin CR. Gut-brain axis mechanisms in IBS. Nat Rev Gastroenterol Hepatol. 2023;20:283&#x2013;98.</Citation></Reference><Reference><Citation>Jones MP, Tack J, Oudenhove L, et al. Gut-brain axis dysregulation in severe IBS: a biomarker study. Gastroenterology. 2025;168:345&#x2013;57.</Citation></Reference><Reference><Citation>Ng SC, Lin S, Zhang Y, et al. Gut microbiota and metabolomic profiles distinguish IBS subtypes with comorbid depression. Gut Microbes. 2023;15:e215353</Citation></Reference><Reference><Citation>Pae CU, Masand PS, Ajwani N, et al. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract. 2007;61:1708&#x2013;18. doi: 10.1111/j.1742-1241.2007.01409.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-1241.2007.01409.x</ArticleId><ArticleId IdType="pubmed">17877658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pae CU, Lee SJ, Han C, et al. Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22:565&#x2013;72. doi: 10.1517/13543784.2013.782392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.2013.782392</ArticleId><ArticleId IdType="pubmed">23506326</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M, T&#xf6;rnblom H, Palsson OS, et al. Multidisciplinary treatment for refractory IBS: integration of gut-directed therapy and cognitive behavioral intervention. Clin Gastroenterol Hepatol. 2022;20:e789&#x2013;802.</Citation></Reference><Reference><Citation>Laird KT. Comparative efficacy of psychological therapies for IBS: a systematic review. Am J Gastroenterol. 2022;117:1376&#x2013;89.</Citation></Reference><Reference><Citation>Ford AC, Lacy BE, Harris LA, et al. Efficacy of antidepressants in IBS. Am J Gastroenterol. 2022;117:568&#x2013;81.</Citation></Reference><Reference><Citation>Ford AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:1773&#x2013;85. doi: 10.1016/S0140-6736(23)01523-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)01523-4</ArticleId><ArticleId IdType="pubmed">37858323</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero P, Ramos-Quiroga JA, Martin-Santos R, et al. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018;32:411&#x2013;20. doi: 10.1007/s40263-018-0519-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-018-0519-3</ArticleId><ArticleId IdType="pubmed">29736744</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller J, Pentyala S, Dilger J, et al. Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Adv Psychopharmacol. 2016;6:185&#x2013;92. doi: 10.1177/2045125316631267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045125316631267</ArticleId><ArticleId IdType="pmc">PMC4910398</ArticleId><ArticleId IdType="pubmed">27354907</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Sant LC, Sarin LM, Magalh&#xe3;es EJM, et al. Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression. J Psychopharmacol . 2020;34:1155&#x2013;62. doi: 10.1177/0269881120922955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881120922955</ArticleId><ArticleId IdType="pubmed">32638662</ArticleId></ArticleIdList></Reference><Reference><Citation>Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018;175:620&#x2013;30. doi: 10.1176/appi.ajp.2018.17060720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2018.17060720</ArticleId><ArticleId IdType="pubmed">29656663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryst J, Kawalec P, Mitoraj AM, et al. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72:543&#x2013;62. doi: 10.1007/s43440-020-00097-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-020-00097-z</ArticleId><ArticleId IdType="pmc">PMC7329804</ArticleId><ArticleId IdType="pubmed">32301056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018;70:621&#x2013;60. doi: 10.1124/pr.117.015198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.117.015198</ArticleId><ArticleId IdType="pmc">PMC6020109</ArticleId><ArticleId IdType="pubmed">29945898</ArticleId></ArticleIdList></Reference><Reference><Citation>Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176:428&#x2013;38. doi: 10.1176/appi.ajp.2019.19020172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2019.19020172</ArticleId><ArticleId IdType="pubmed">31109201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Farchione T, Potter A, et al. Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class. N Engl J Med. 2019;381:1&#x2013;4. doi: 10.1056/NEJMp1903305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1903305</ArticleId><ArticleId IdType="pubmed">31116916</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials. 2022;23:552. doi: 10.1186/s13063-022-06492-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06492-6</ArticleId><ArticleId IdType="pmc">PMC9264306</ArticleId><ArticleId IdType="pubmed">35804433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393&#x2013;407. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilmore AH, Kuplicki R, McDonald D, et al. Medication use is associated with distinct microbial features in anxiety and depression. Mol Psychiatry. 2025;30:2545&#x2013;57. doi: 10.1038/s41380-024-02857-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-024-02857-2</ArticleId><ArticleId IdType="pmc">PMC12092254</ArticleId><ArticleId IdType="pubmed">39794490</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn SD, Kaptchuk TJ, Park JB, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil. 2007;19:630&#x2013;7. doi: 10.1111/j.1365-2982.2007.00937.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2007.00937.x</ArticleId><ArticleId IdType="pubmed">17640177</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome. Gastroenterology. 2022;162:1752&#x2013;4. doi: 10.1053/j.gastro.2022.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.01.021</ArticleId><ArticleId IdType="pubmed">35077757</ArticleId></ArticleIdList></Reference><Reference><Citation>Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124:303&#x2013;17. doi: 10.1053/gast.2003.50055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2003.50055</ArticleId><ArticleId IdType="pubmed">12557136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Deng C-M, Zeng Y, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ. 2024;385:e078218. doi: 10.1136/bmj-2023-078218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2023-078218</ArticleId><ArticleId IdType="pmc">PMC11957566</ArticleId><ArticleId IdType="pubmed">38808490</ArticleId></ArticleIdList></Reference><Reference><Citation>Creed F, Guthrie E, Ratcliffe J, et al. Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust N Z J Psychiatry. 2005;39:807&#x2013;15. doi: 10.1080/j.1440-1614.2005.01686.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/j.1440-1614.2005.01686.x</ArticleId><ArticleId IdType="pubmed">16168039</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vdahl J, T&#xf6;rnblom H, Ringstr&#xf6;m G, et al. Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome. Aliment Pharmacol Ther. 2022;55:1501&#x2013;11. doi: 10.1111/apt.16934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16934</ArticleId><ArticleId IdType="pmc">PMC9324196</ArticleId><ArticleId IdType="pubmed">35505463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou S, Hassan R, Nee J, et al. Are They Side Effects? Extraintestinal Symptoms Reported During Clinical Trials of Irritable Bowel Syndrome May Be More Severe at Baseline. Clin Gastroenterol Hepatol. 2022;20:2888&#x2013;94. doi: 10.1016/j.cgh.2022.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.03.018</ArticleId><ArticleId IdType="pmc">PMC9500110</ArticleId><ArticleId IdType="pubmed">35339669</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Silva A, Marshall DA, Vallance JK, et al. Meditation and Yoga for Irritable Bowel Syndrome: A Randomized Clinical Trial. Am J Gastroenterol. 2023;118:329&#x2013;37. doi: 10.14309/ajg.0000000000002052.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000002052</ArticleId><ArticleId IdType="pmc">PMC9889201</ArticleId><ArticleId IdType="pubmed">36422517</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol. 2002;97:954&#x2013;61. doi: 10.1111/j.1572-0241.2002.05615.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2002.05615.x</ArticleId><ArticleId IdType="pubmed">12003432</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43:400&#x2013;11. doi: 10.1023/a:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Rej A, Sanders DS, Shaw CC, et al. Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet. Clin Gastroenterol Hepatol. 2022;20:2876&#x2013;87. doi: 10.1016/j.cgh.2022.02.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.02.045</ArticleId><ArticleId IdType="pubmed">35240330</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920&#x2013;4. doi: 10.3109/00365529709011203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365529709011203</ArticleId><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361&#x2013;70. doi: 10.1111/j.1600-0447.1983.tb09716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther. 2010;32:811&#x2013;20. doi: 10.1111/j.1365-2036.2010.04402.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04402.x</ArticleId><ArticleId IdType="pubmed">20629976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258&#x2013;66. doi: 10.1097/00006842-200203000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006842-200203000-00008</ArticleId><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty T, Wajs E, Melkote R, et al. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. CNS Drugs. 2020;34:299&#x2013;310. doi: 10.1007/s40263-020-00699-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-020-00699-4</ArticleId><ArticleId IdType="pmc">PMC7048867</ArticleId><ArticleId IdType="pubmed">31994024</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JB, Fedgchin M, Daly E, et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol Psychiatry. 2016;80:424&#x2013;31. doi: 10.1016/j.biopsych.2015.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2015.10.018</ArticleId><ArticleId IdType="pubmed">26707087</ArticleId></ArticleIdList></Reference><Reference><Citation>Delfino RS, Del-Porto JA, Surjan J, et al. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. J Affect Disord. 2021;278:515&#x2013;8. doi: 10.1016/j.jad.2020.09.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.09.056</ArticleId><ArticleId IdType="pubmed">33017679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavakbasi E, Baune BT. Combination of Acute and Maintenance Esketamine Treatment With Adjunctive Long-Term Vagus Nerve Stimulation in Difficult-to-Treat Depression. Neuromodulation. 2024;27:766&#x2013;73. doi: 10.1016/j.neurom.2023.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurom.2023.12.004</ArticleId><ArticleId IdType="pubmed">38340111</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson DJ, Gogate JP, Kern Sliwa JK, et al. Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. J Clin Psychiatry. 2022;83:21m14318. doi: 10.4088/JCP.21m14318.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.21m14318</ArticleId><ArticleId IdType="pubmed">36149841</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ. 1990;300:439&#x2013;40. doi: 10.1136/bmj.300.6722.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.300.6722.439</ArticleId><ArticleId IdType="pmc">PMC1662249</ArticleId><ArticleId IdType="pubmed">2107897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>